Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE, NSE |
| IPO Issue Type | Book Build Issue |
| Issue Size | ₹1023.54 Cr |
| Fresh Issue | ₹149.96 Cr |
| Offer for Sale | ₹873.58 Cr |
| Face Value | ₹2 Per Equity Share |
| Price Band | ₹635.00-662.00 per share |
| Discount | Retail: 0.00,Employee: 61.00 |
| BSE Code | 543399 |
| NSE Code | TARSONS |
| Registrar | Kfin Technologies Ltd. |
| Lead Managers | ICICI Securities Ltd. |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 22 shares and in multiples thereof
Tarsons Products Limited is a leading Indian life sciences company with more than three decades of experience in the production and supply of labware products. The company manufactures a range of quality labware products that helps advance scientific discovery and improve healthcare systems. The company's product portfolio is classified into three broad categories including consumables, reusables, and others. As of March 31, 2021, the company has a diversified product portfolio with over 1,700 SKUs across 300 products.
Trason's products are used in various laboratories across research organizations, academic institutes, pharmaceutical companies, Contract Research Organizations (CRO), diagnostic companies, and hospitals. The company has many reputed institutes, medical labs, and hospitals as its key clients.
Currently, the company has 5 manufacturing facilities located in West Bengal spread across approximately 20,000 sq. mts of area. The company has a strong distribution network across India comprising of over 141 authorized distributors as of March 31, 2021 and supplies its products to more than 40 countries.
Competitive Strengths:
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment/prepayment of certain borrowings of our Company | 78.54 |
| 2 | Funding capital expenditure for the Proposed Expansion | 62.00 |
| 3 | General corporate purposes | 1.62 |
| Period Ended | 30 Jun 2021 | 31 Mar 2021 | 31 Mar 2020 | 31 Mar 2019 |
|---|---|---|---|---|
| Assets | 364.77 | 295.95 | 248.71 | 211.96 |
| Total Income | 71.13 | 234.29 | 180.05 | 184.72 |
| Profit After Tax | 24.84 | 68.87 | 40.53 | 38.96 |
| EBITDA | 38.74 | 108.82 | 73.41 | 77.64 |
| NET Worth | 268.96 | 244.34 | 197.57 | 135.27 |
| Reserves and Surplus | 258.77 | 244.15 | 197.37 | 135.08 |
| Total Borrowing | 64.49 | 33.50 | 36.00 | 64.76 |
| Amount in ₹ Crore | ||||
